Motley Fool News Releases and Press Releases From 07/20/24

PFE - Could Pfizer Become a Top Weight Loss Drug Stock? Don't Count on It.

2024-07-20 10:00:00 ET On July 11, Pfizer (NYSE: PFE) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage weight loss programs into mid-stage trials. In due time, the mo...

ETH - Is Solana on Track to Hit $200 by 2025?

2024-07-20 09:57:00 ET The Solana (CRYPTO: SOL) cryptocurrency has shown remarkable growth since its inception. It has emerged as a leading blockchain platform for decentralized applications (dApps) via its efficient execution of smart contracts . Anatoly Yakovenko and his S...

SOL - Is Solana on Track to Hit $200 by 2025?

2024-07-20 09:57:00 ET The Solana (CRYPTO: SOL) cryptocurrency has shown remarkable growth since its inception. It has emerged as a leading blockchain platform for decentralized applications (dApps) via its efficient execution of smart contracts . Anatoly Yakovenko and his S...

MGK - 1 No-Brainer Artificial Intelligence (AI) ETF to Buy Right Now for Less Than $1,000

2024-07-20 09:45:00 ET You'd be hard-pressed to find a topic that has dominated the business and tech world over the past couple of years more than artificial intelligence (AI). It's been more unavoidable than traffic in Los Angeles. Despite being around for decades (yes, decades), AI w...

U - Unity Software Stock Trades Near All-Time Lows. Here's What It Would Take to Outperform the S&P 500 Over the Next 5 Years

2024-07-20 09:40:00 ET In 2021, the metaverse was creating the loudest buzz in the investing world, and Unity Software (NYSE: U) was seen as a key architect of that future. The stock soared past $200 per share because management said it expected to grow revenue at a compound annual ...

NFLX - Netflix's Game-Changing Ideas: What Investors Need to Know

2024-07-20 09:37:00 ET Media-streaming veteran Netflix (NASDAQ: NFLX) reported second-quarter results on Thursday, July 10. The results were consistently slightly better than management's guidance, edging out Wall Street's consensus estimates across the board. As ...

ALT - Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?

2024-07-20 09:30:00 ET Eli Lilly and Novo Nordisk are, for now, the undisputed champions of the market for weight-loss medicines. Thanks to the outrageous popularity of Lilly's drug Zepbound and Novo's product Wegovy, the biggest contest of the moment will go to whoever can ramp up ...

TERN - Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?